123 related articles for article (PubMed ID: 7041239)
21. [Feasibility and reproductibility of a euglycemic hyperinsulinic glucose clamp technic].
Gin H; Brunel PG; Brottier E; Aubertin J; Drouin P; Debry G
Diabete Metab; 1984 Jan; 10(1):36-8. PubMed ID: 6373424
[TBL] [Abstract][Full Text] [Related]
22. A new test of peripheral insulin sensitivity in vivo using artificial beta cell.
Valenta LJ; Elias AN; Grossman M; Tanner SM; Friis R
Life Sci; 1982 Mar; 30(10):867-73. PubMed ID: 7040887
[TBL] [Abstract][Full Text] [Related]
23. Acute and chronic effects of dexfenfluramine on glucose and insulin response to intravenous glucose in diabetic and non-diabetic obese subjects.
Glaser B; Raveh Y; Norynberg C; Berry E; Lavielle R; Nathan C; Cerasi E
Diabetes Res; 1992; 19(4):165-76. PubMed ID: 1343113
[TBL] [Abstract][Full Text] [Related]
24. Development and evaluation of a glucose analyzer for a glucose controlled insulin infusion system ((Biostator).
Fogt EJ; Dodd LM; Jenning EM; Clemens AH
Clin Chem; 1978 Aug; 24(8):1366-72. PubMed ID: 679460
[TBL] [Abstract][Full Text] [Related]
25. Control algorithms for artificial beta cell.
Clemens AH
Horm Metab Res Suppl; 1979; (8):35-8. PubMed ID: 395086
[TBL] [Abstract][Full Text] [Related]
26. A comparison of the artificial pancreas (glucose controlled insulin infusion system) and a manual technique for assessing insulin sensitivity during euglycaemic clamping.
Ponchner M; Heine RJ; Pernet A; Hanning I; Francis AJ; Cook D; Orskov H; Alberti KG
Diabetologia; 1984 Jun; 26(6):420-5. PubMed ID: 6381189
[TBL] [Abstract][Full Text] [Related]
27. Hormonal and metabolic profiles in insulin-dependent diabetics under subcutaneous conventional and artificial endocrine pancreas (glucose continuous insulin infusion system Biostator) treatment.
Calabrese G; Bueti A; Santeusanio F; Giombolini A; Zega G; Bellomo G; Antonella MA; Angeletti G; Massi-Benedetti M; Brunetti P
J Endocrinol Invest; 1983 Feb; 6(1):1-8. PubMed ID: 6341441
[No Abstract] [Full Text] [Related]
28. Clinical usefulness of artificial endocrine pancreas "Biostator" in management of unstable diabetics.
Ohno M; Ito K; Saito S; Kageyama S; Ikeda Y; Tanese T; Abe M
Tohoku J Exp Med; 1983 Dec; 141 Suppl():723-32. PubMed ID: 6393446
[TBL] [Abstract][Full Text] [Related]
29. Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion.
Pickup JC; Viberti GC; Bilous RW; Keen H; Alberti KG; Home PD; Binder C
Diabetologia; 1982 Mar; 22(3):175-9. PubMed ID: 7042428
[TBL] [Abstract][Full Text] [Related]
30. Insulin delivery rate in response to glucose infusion in normal and diabetic subjects.
Asano T; Sasaki H; Okumura M
Endocrinol Jpn; 1978 Dec; 25(6):519-27. PubMed ID: 751797
[TBL] [Abstract][Full Text] [Related]
31. Effect of artificial pancreas treatment on peripheral nerve function in diabetes.
Service FJ; Daube JR; O'Brien PC; Dyck PJ
Neurology; 1981 Nov; 31(11):1375-80. PubMed ID: 7031500
[TBL] [Abstract][Full Text] [Related]
32. Glucose control in mobile type 1 (insulin-dependent) diabetic patients by means of a semi-automatic feedback controlled insulin infusion system.
Piwernetz K; Renner R; Hepp KD
Diabetologia; 1982 Sep; 23(3):229-34. PubMed ID: 7128971
[TBL] [Abstract][Full Text] [Related]
33. Acute and steady-state insulin responses to glucose in nonobese diabetic subjects.
Lerner RL; Porte D
J Clin Invest; 1972 Jul; 51(7):1624-31. PubMed ID: 4555783
[TBL] [Abstract][Full Text] [Related]
34. In vivo comparison of different algorithms for the artificial beta-cell.
Fischer U; Detschew W; Jutzi E; Albrecht G; Abel P; Salzsieder E; Freyse EJ; Frenzel S; Lemke K
Artif Organs; 1985 May; 9(2):173-9. PubMed ID: 4015454
[TBL] [Abstract][Full Text] [Related]
35. Reproducibility of insulin dosage on consecutive days of blood glucose control by an artificial beta-cell in brittle diabetic patients.
Bruns W; Bombor H; Jutzi E; Ratzmann KP; Schulz B; Abel P; Fischer U
Diabetes Care; 1983; 6(2):112-7. PubMed ID: 6343014
[TBL] [Abstract][Full Text] [Related]
36. Comparison of a perfusion syringe (Mill Hill Infusor) and a glucose-controlled insulin infusion system in the regulation of diabetes mellitus.
Stavljenić A; Granić M; Topić B; Skrabalo Z
Horm Metab Res Suppl; 1979; (8):207-11. PubMed ID: 395083
[TBL] [Abstract][Full Text] [Related]
37. [Use of the blood glucose-controlled Biostator for intravenous infusion of insulin for optimal insulin therapy (so-called corrective feedback)].
Sieradzki J; Szurkowska M
Pol Arch Med Wewn; 1986 Feb; 75(2):127-34. PubMed ID: 3748830
[No Abstract] [Full Text] [Related]
38. Glucagon responses to intravenous arginine and oral glucose in insulin-dependent diabetic patients during six months conventional or continuous subcutaneous insulin infusion.
Hermansen K; Schmitz O; Boye N; Christensen CK; Christiansen JS; Alberti KG; Orskov H; Mogensen CE
Metabolism; 1988 Jul; 37(7):640-4. PubMed ID: 3290622
[TBL] [Abstract][Full Text] [Related]
39. A double-blind study of the efficacy of neutral human and porcine insulin in type I diabetes using a glucose-controlled insulin infusion system.
Christensen SE; Schmitz O; Hansen AP; Jensen I; Heding L
Metabolism; 1984 Sep; 33(9):864-8. PubMed ID: 6381963
[TBL] [Abstract][Full Text] [Related]
40. Practical closed-loop insulin delivery. A system for the maintenance of overnight euglycemia and the calculation of basal insulin requirements in insulin-dependent diabetics.
White NH; Skor D; Santiago JV
Ann Intern Med; 1982 Aug; 97(2):210-3. PubMed ID: 7103278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
